Drugs.com is the most popular, comprehensive and up-to-date source of drug information online. Providing free, peer-reviewed, accurate and independent data on more than 24,000 prescription drugs, over-the-counter medicines & natural products.
Teva and Alvotech Announce FDA Approval of Interchangeability for Selarsdi (ustekinumab-aekn) with Stelara (ustekinumab)
PARSIPPANY, N.J. & REYKJAVÍK, Iceland, May 05, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries...
Depressive Symptoms Increased for U.S. Adults During Pandemic
The prevalence of depressive symptoms increased among U.S. adults during the pandemic, according to a research letter published online May 5 in JAMA Internal...
Ultraprocessed Food Consumption Linked to Nonmotor Prodromal Parkinson Disease
Long-term consumption of ultraprocessed foods (UPF) is associated with nonmotor prodromal Parkinson disease (PD) features, according to a study published...
Real-Time AI-Driven Decision Support Aids Catheter Ablation
An artificial intelligence (AI)-driven model can significantly improve procedural safety in cardiac electrophysiology with real-time decision support,...
Nearly Two-Thirds of U.S. Adults Have Experienced In-Person Gun Violence
There are significant racial/ethnic and socioeconomic disparities in gun violence exposure (GVE) within the United States, according to a study published...
Quality Improvement Program Aids Antibiotic Duration for Common Infections in Children
A quality improvement program can improve recommended antibiotic duration in children for both acute otitis media (AOM) and community-acquired pneumonia...
Dr. Vinay Prasad to Head FDA Vaccine, Biologics Division
WEDNESDAY, May 7, 2025 — The U.S. Food and Drug Administration (FDA) has chosen Dr. Vinay Prasad, a professor at the University of California-San...
Top FDA Inspection Official to Retire Amid Staff Frustration
WEDNESDAY, May 7, 2025 — The official in charge of federal food and drug safety inspections will retire May 14. Michael Rogers, associate commissioner...
Europe Launches $565 Million Campaign to Attract U.S. Scientists
WEDNESDAY, May 7, 2025 — The European Union is looking to capitalize on the Trump administration's dismantling of U.S. research programs to beef...
Boehringer Ingelheim Starts Phase II Study of its Potential First-in-Class Oral Compound as a Treatment for Geographic Atrophy
Boehringer Ingelheim today announces the start of the JADE Phase II clinical study (NCT06769048), investigating the efficacy and safety of BI 1584862 as...
Vanda Announces Bysanti NDA Filing; FDA Decision Expected in Early 2026
Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) informed Vanda that the New Drug Application...
Alterity Therapeutics Granted U.S. FDA Fast Track Designation for ATH434 to Treat Multiple System Atrophy
MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 5 May 2025 Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the...
Body Mass Index (BMI): What It Tells You — And What It Doesn’t
SUNDAY, May 4, 2025 — Body Mass Index, or BMI, is a number that reflects the relationship between your height and weight. It's widely used in healthcare...
Recently Added
Recently added consumer and prescribing information: Miudella, Opdivo Qvantig, Alyftrek, Crenessity, Ensacove, Steqeyma, Yesintek, Revuforj, Danziten, Aucatzyl
For Consumers
- Cerner Multum Drug Information
- Micromedex Advanced Consumer
- Natural Product Information for the Consumer
For Professionals
- FDA Professional Information
- Professional Patient Advice
- ASHP Monographs (AHFS DI)
- Micromedex CareNotes
- Natural Product Information
For Researchers
Latest FDA New Drug Approvals
- Imaavy Imaavy (nipocalimab-aahu) is a neonatal Fc receptor (FcRn) blocker used for the treatment of generalized myasthenia gravis.
- Atzumi Atzumi (dihydroergotamine mesylate) is a nasal powder formulation of the ergotamine derivative dihydroergotamine mesylate for the acute...
- Zevaskyn Zevaskyn (prademagene zamikeracel) is an autologous, cell sheet-based gene therapy for the treatment of recessive dystrophic epidermolysis bullosa.
Drugs in Development (Not yet approved)
- Yutrepia Yutrepia (treprostinil) is an inhaled dry powder formulation of treprostinil tentatively approved for the treatment of pulmonary arterial...